B2BINPAY
14.2.2024 09:22:28 CET | Business Wire | Press release
B2BinPay, the trusted blockchain-backed payment platform, has officially released its version 19 update to the public. This upgrade boasts many enhancements, including state-of-the-art instant swaps and expanded support for various blockchains. As always, B2BinPay remains dedicated to providing a seamless and secure platform for all cryptocurrency transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214263094/en/
B2BinPay v19 goes live with instant swaps and expanded blockchain support (Photo: Business Wire)
New Instant Swaps and Competitive VWAP-powered Rates
Swaps have become a preferred strategy for managing digital assets due to the direct exchange of cryptocurrencies between different addresses. This is a contrarian approach to conventional exchanges, which use the order books system for asset trading.
With B2BinPay, clients can easily access instant swaps without navigating through complicated order books and comparing prices across different venues. This is made possible with the Volume-Weighted Average Price (VWAP) tool, which automatically selects the best available price from multiple centralised platforms based on transaction volume.
In addition, the use of swaps by B2BinPay clients eliminates two blockchain commission costs, namely, the transaction to the centralised exchange and the transaction back to the B2BinPay wallet, which adds flexibility and cost-effectiveness in dealing with digital assets.
Instant swaps can be accessed through the dedicated Swaps Tab on the platform's front-end menu, along with separate wallets for each crypto asset.
Commission-Free Wallet Funding, Smooth Swapping Process
The latest release introduces a customised top-up process for swap wallets tailored to different user categories. Those with digital wallets can now take advantage of swift transactions for instant fund transfers, while owners of blockchain wallets benefit from on-chain transactions that offer both transparency and security through recorded data on the blockchain. It is crucial to note that topping up must be done in the wallet's designated currency.
In addition, users can enjoy a commission-free top-up process from their B2BinPay accounts. Note that blockchain wallets will still incur a minimal fee for on-chain transactions.
New Blockchain Network Integration: Avalanche and Polygon
B2BinPay's latest release has integrated support for two in-demand blockchains, Polygon and Avalanche. This integration brings an array of stablecoin transaction options to the platform, including popular choices like USDT, USDC, DAI, FRAX, TUSD, and EUROC on new networks.
Known for its scalability and minimal transaction fees, Polygon is a popular choice for a large number of crypto users. In comparison, Avalanche shines with its high throughput and rapid processing times, providing a powerful platform for speedy transfers.
Final Remarks
B2BinPay continues to push the boundaries of crypto processing with their latest version 19 release. This update offers clients even more flexibility, allowing them to access more blockchains and cryptocurrencies and make instant exchanges with swap wallets.
The team isn't stopping there – they are actively working on reducing fees to make their services even more cost-effective for all clients in future releases. This dedication to continuous improvement demonstrates B2BinPay's commitment to meeting the evolving needs of businesses and startups alike.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214263094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom